A cancer trial has reportedly become the first in the world to completely remove the disease in every patient, according to a study published on June 5 in The New England Journal of Medicine.
The study, “PD-1 Blockade in Mismatch Repair—Deficient, Locally Advanced Rectal Cancer,” was conducted among 12 rectal cancer patients, all of whom had a “clinical complete response,” according to the authors, led by Dr. Andrea Cercek of the Memorial Sloan Kettering Cancer Center in New York.
Doctors have been unable to see any evidence of tumors among the patients when using magnetic resonance imaging, fludeoxyglucose F 18 injections, physical examinations, or endoscopic evaluations, according to researchers.
The patients also continued to show no signs of cancer during follow-ups ranging from six months to 25 months and haven’t had to undergo surgery or receive radiation and chemotherapy.
“No adverse events of grade 3 or higher have been reported,” the study authors noted.